A functional alternative splicing mutation in human tryptophan hydroxylase-2

Molecular Psychiatry

Volumn 16, Issue 12, 2011, Pages 1169-1176

  Zhang, X ^a,b   Nicholls, P J ^a   Laje, G ^c   Sotnikova, T D ^a,d   Gainetdinov, R R ^a,d   Albert, P R ^e   Rajkowska, G ^f   Stockmeier, C A ^f,g   Speer, M C ^a   Steffens, D C ^a   Austin, M C ^f   McMahon, F J ^c   Krishnan, K R R ^a   Garcia Blanco, M A ^a   Caron, M G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

alternative splicing; serotonin (5 HT); SNP; TPH2

Indexed keywords

GENOMIC DNA; MESSENGER RNA; RNA; TRYPTOPHAN HYDROXYLASE 2;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HOMEOSTASIS; HUMAN; HUMAN TISSUE; PREDICTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM;

ALTERNATIVE SPLICING; ANIMALS; BRAIN STEM; CELL LINE, TRANSFORMED; DEPRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; PC12 CELLS; PEDIGREE; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; SEROTONIN; TRYPTOPHAN HYDROXYLASE;

EID: 81755176831     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2010.99     Document Type: Article

References (54)

1. Lesch KP. Gene-environment interaction and the genetics of depression. J Psychiatry Neurosci 2004; 29: 174-184. (Pubitemid 38829854)
2. Bobb AJ, Castellanos FX, Addington AM, Rapoport JL. Molecular genetic studies of ADHD: 1991 to 2004. Am J Med Genet B Neuropsychiatr Genet 2005; 132: 109-125. (Pubitemid 40066207)
3. Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA. Recent advances in the neurobiology of schizophrenia. Mol Interv 2003; 3: 27-39.
4. Arango V, Huang YY, Underwood MD, Mann JJ. Genetics of the serotonergic system in suicidal behavior. J Psychiatr Res 2003; 37: 375-386. (Pubitemid 36808811)
5. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-1531. (Pubitemid 26403928)
6. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005; 8: 828-834. (Pubitemid 43085851)
7. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299: 76. (Pubitemid 36042402)
8. Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 2004; 305: 217. (Pubitemid 38886729)
9. Zhang X, Gainetdinov RR, Beaulieu JM, Sotnikova TD, Burch LH, Williams RB et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 2005; 45: 11-16. (Pubitemid 40075345)
10. Scheuch K, Lautenschlager M, Grohmann M, Stahlberg S, Kirchheiner J, Zill P et al. Characterization of a functional promoter polymorphism of the human tryptophan hydroxylase 2 gene in serotonergic raphe neurons. Biol Psychiatry 2007; 62: 1288-1294. (Pubitemid 350060888)
11. Chen GL, Vallender EJ, Miller GM. Functional characterization of the human TPH2 50 regulatory region: untranslated region and polymorphisms modulate gene expression in vitro. Hum Genet 2008; 122: 645-657.
12. Cichon S, Winge I, Mattheisen M, Georgi A, Karpushova A, Freudenberg J et al. Brain-specific tryptophan hydroxylase 2 (TPH2): a functional Pro206Ser substitution and variation in the 50-region are associated with bipolar affective disorder. Hum Mol Genet 2008; 17: 87-97.
13. Zhang X, Beaulieu JM, Gainetdinov RR, Caron MG. Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2. Cell Mol Life Sci 2006; 63: 6-11. (Pubitemid 43100277)
14. Zill P, Baghai TC, Zwanzger P, Schule C, Eser D, Rupprecht R et al. SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry 2004; 9: 1030-1036. (Pubitemid 39524291)
15. Haghighi F, Bach-Mizrachi H, Huang YY, Arango V, Shi S, Dwork AJ et al. Genetic architecture of the human tryptophan hydroxylase Gene: existence of neural isoforms and relevance for major depression. Mol Psychiatry 2008; 13: 813-820. (Pubitemid 352032109)
16. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet 2004; 36: 40-45. (Pubitemid 38056206)
17. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003; 72: 291-336. (Pubitemid 36930448)
18. Carstens RP, McKeehan WL, Garcia-Blanco MA. An intronic sequence element mediates both activation and repression of rat fibroblast growth factor receptor 2 pre-mRNA splicing. Mol Cell Biol 1998; 18: 2205-2217. (Pubitemid 28152669)
19. Mazumder B, Seshadri V, Fox PL. Translational control by the 30-UTR: the ends specify the means. Trends Biochem Sci 2003; 28: 91-98. (Pubitemid 36165138)
20. Rush AJ, Trivedi M, Fava M. Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry 2003; 160: 237.
21. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ,Wilson AF et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804-814.
22. Levinson DF, Zubenko GS, Crowe RR, DePaulo RJ, Scheftner WS, Weissman MM et al. Genetics of recurrent early-onset depression (GenRED): design and preliminary clinical characteristics of a repository sample for genetic linkage studies. Am J Med Genet B Neuropsychiatr Genet 2003; 119: 118-130. (Pubitemid 37064064)
23. Zhang MQ. Statistical features of human exons and their flanking regions. Hum Mol Genet 1998; 7: 919-932. (Pubitemid 28221257)
24. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD et al. Genome-wide survey of human alternative premRNA splicing with exon junction microarrays. Science 2003; 302: 2141-2144. (Pubitemid 38017950)
25. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 1992; 90: 41-54.
26. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003; 17: 419-437. (Pubitemid 36258756)
27. Garcia-Blanco MA, Baraniak AP, Lasda EL. Alternative splicing in disease and therapy. Nat Biotechnol 2004; 22: 535-546. (Pubitemid 38585905)
28. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002; 3: 285-298. (Pubitemid 34279797)
29. Licatalosi DD, Darnell RB. Splicing regulation in neurologic disease. Neuron 2006; 52: 93-101. (Pubitemid 44466357)
30. Li Q, Lee JA, Black DL. Neuronal regulation of alternative premRNA splicing. Nat Rev Neurosci 2007; 8: 819-831. (Pubitemid 350006218)
31. Fu XD, Maniatis T. Isolation of a complementary DNA that encodes the mammalian splicing factor SC35. Science 1992; 256: 535-538.
32. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003; 31: 3568-3571. (Pubitemid 37442199)
33. Dauksaite V, Akusjarvi G. Human splicing factor ASF/SF2 encodes for a repressor domain required for its inhibitory activity on pre-mRNA splicing. J Biol Chem 2002; 277: 12579-12586. (Pubitemid 34952616)
34. Fitzpatrick PF. Tetrahydropterin-dependent amino acid hydroxylases. Annu Rev Biochem 1999; 68: 355-381. (Pubitemid 29449197)
35. Carkaci-Salli N, Flanagan JM, Martz MK, Salli U, Walther DJ, Bader M et al. Functional domains of human tryptophan hydroxylase 2 (hTPH2). J Biol Chem 2006; 281: 28105-28112. (Pubitemid 44414524)
36. Murphy KL, Zhang X, Gainetdinov RR, Beaulieu JM, Caron MG. A regulatory domain in the N terminus of tryptophan hydroxylase 2 controls enzyme expression. J Biol Chem 2008; 283: 13216-13224.
37. Harvey M, Gagne B, Labbe M, Barden N. Polymorphisms in the neuronal isoform of tryptophan hydroxylase 2 are associated with bipolar disorder in French Canadian pedigrees. Psychiatr Genet 2007; 17: 17-22. (Pubitemid 44953342)
38. Lopez VA, Detera-Wadleigh S, Cardona I, Kassem L, McMahon FJ. Nested association between genetic variation in tryptophan hydroxylase II, bipolar affective disorder, and suicide attempts. Biol Psychiatry 2007; 61: 181-186. (Pubitemid 46091659)
39. McKinney J, Johansson S, Halmoy A, Dramsdahl M, Winge I, Knappskog PM et al. A loss-of-function mutation in tryptophan hydroxylase 2 segregating with attention-deficit/hyperactivity disorder. Mol Psychiatry 2008; 13: 365-367. (Pubitemid 351399825)
40. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 2008; 105: 1333-1338. (Pubitemid 351397053)
41. Pey AL, Desviat LR, Gamez A, Ugarte M, Perez B. Phenylketonuria: genotype-phenotype correlations based on expression analysis of structural and functional mutations in PAH. Hum Mutat 2003; 21: 370-378. (Pubitemid 36389826)
42. Grohmann M, Hammer P, Walther M, Paulmann N, Buttner A, Eisenmenger W et al. Alternative splicing and extensive RNA editing of human TPH2 transcripts. PLoS One 2010; 5: e8956.
43. Wright A, Charlesworth B, Rudan I, Carothers A, Campbell H. A polygenic basis for late-onset disease. Trends Genet 2003; 19: 97-106. (Pubitemid 36120667)
44. Goldstein DB. Common genetic variation and human traits. N Engl J Med 2009; 360: 1696-1698.
45. Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its contribution to complex traits. Nat Rev Genet 2009; 10: 241-251.
46. Malhotra AK, Murphy Jr GM, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780-796. (Pubitemid 38625331)
47. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004; 9: 879-889. (Pubitemid 39273536)
48. March JS, Vitiello B. Clinical messages from the treatment for adolescents with depression study (TADS). Am J Psychiatry 2009; 166: 1118-1123.
49. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29: 1765-1781. (Pubitemid 39336788)
50. Oquendo MA, Friend JM, Halberstam B, Brodsky BS, Burke AK, Grunebaum MF et al. Association of comorbid posttraumatic stress disorder and major depression with greater risk for suicidal behavior. Am J Psychiatry 2003; 160: 580-582. (Pubitemid 41094272)
51. Fineberg NA, Fourie H, Gale TM, Sivakumaran T. Comorbid depression in obsessive compulsive disorder (OCD): symptomatic differences to major depressive disorder. J Affect Disord 2005; 87: 327-330. (Pubitemid 41039956)
52. Sher L. Serotonin and suicidal behavior in patients with comorbid depression and alcoholism. Am J Addict 2006; 15: 198.
53. Moffitt TE, Harrington H, Caspi A, Kim-Cohen J, Goldberg D, Gregory AM et al. Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. Arch Gen Psychiatry 2007; 64: 651-660. (Pubitemid 46878666)
54. Krishnan KR. Psychiatric disease in the genomic era: rational approach. Mol Psychiatry 2005; 10: 978-984. (Pubitemid 41541983)